ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Top Brokers

More Brokers

Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
AI Sign In Premium IconPremium Help Menu
FTSE 100
8,201.54
-0.28%
Dow Jones
42,523.63
0.54%
Gold vs US Dollar
2,671.68
0.12%
Brent Oil
79.515
-0.95%
Bitcoin
96,821.66
2.45%
Pepperstone
Advertisement
Registration Strip Icon for charts Register for streaming realtime charts, analysis tools, and prices.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. Canada
  5. TSX

  6. Medicenna Therapeutics Corp (MDNA) Share Price

MDNA Medicenna Therapeutics Corp

1.31
-0.03 (-2.24%)
Last Updated: 18:42:19
Delayed by 15 minutes
 Name  Symbol  Market  Type  ISIN  Description 
 Medicenna Therapeutics Corp TSX:MDNA Toronto Stock Exchange Common Stock  
     Change  % Chg  Cur  Bid  Offer  High  Low  Open  Volume  Chg Time
Upgrade Icon
 		 RN  NRN 
   -0.03 -2.24 1.31 1.31 1.33 1.34 1.30 1.32 103,777 18:42:19   
 Sector  Turnover  Profit  EPS - Basic  PE ratio  Mkt Cap 
 Biological Pds,ex Diagnstics  -25.47M -0.3657 -3.58 93.31M
 Type  Size  Price  Time  Units 
  15,400 1.31 18:41:48 CAD
 
Recent News
DateTimeSource
HeadlineMore MDNA News
13/12/202413:30GLOBEMedicenna Presents Preclinical Data on MDNA11 as First Step to Shrink Tumors Before Surgery and Prevent Metastasis at the 2024 San Antonio Breast Cancer Symposium (SABCS)
05/12/202412:35GLOBEMedicenna Provides Clinical Update and Announces First Complete Responder in MDNA11 and KEYTRUDA® (pembrolizumab) Combination Dose Escalation Arm of the ABILITY-1 Study
27/11/202412:00GLOBEUpdated MDNA11 Monotherapy and Combination Clinical Data from the Ongoing Phase 1/2 ABILITY-1 Study to be Presented at the 2024 Immunotherapy Bridge Conference
25/11/202412:30GLOBEMedicenna Presents Preclinical Data on MDNA11 and Bizaxofusp at the 2024 Annual Meeting of the Society for Neuro-Oncology (SNO)
15/11/202412:30GLOBEMedicenna Reports Second Quarter Fiscal 2025 Financial Results and Corporate Update
13/11/202412:00GLOBEMedicenna Announces Upcoming Presentations at the 29th Annual Meeting of the Society for Neuro-Oncology (SNO) and the 2024 San Antonio Breast Cancer Symposium (SABCS)
11/11/202412:00GLOBEMedicenna Announces Positive Single-Agent Activity of MDNA11 from Dose Expansion Cohort and Encouraging Safety Profile in Combination with KEYTRUDA® (pembrolizumab) at the 39th Annual Meeting of SITC
Period
Draw mode


Loading Follow Feed...

Latest Medicenna Therapeutics Corp Articles

Go Ad-Free

Subscribe to Ad free and enjoy an ad-free experience

No Ads

Try Now

Keep the Ads